Stock market crash: Here are the stocks I’d buy if equities collapse in September

We don’t know if another stock market crash is imminent but it is good to be prepared. Buying low is the best way for shareholders to pick up bargains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the stock market crash in March, investors have been wondering if another one is imminent. The rebound in equity markets lately does not match with the economic fallout of the Covid-19 pandemic, and this is making shareholders nervous.

Stock market crash or correction

A market correction differs slightly from a crash. A crash is a dramatic decline of stock prices on a single day, whereas a correction is when a financial index falls over 10% below its most recent high and can last days, weeks, or months.

The European Union’s securities watchdog warns a sustained correction is likely. This is because recovery, and a bounce back to a pre-pandemic economy, is likely to take a very long time. The International Monetary Fund expects the eurozone GDP to fall over 10% this year, with slow recovery next year. For this reason, a September stock market crash is not out of the question, but I’m no psychic, so will have to wait and see. I think it’s best to prepare for every eventuality, and as a long-term value investor, keeping core principles in mind is a good place to start.

Dividend-paying stocks

I want to benefit from the power of dividend compounding and long-term growth. To do this I search for stocks that are likely to go the distance and make a sustained recovery from market lows. Companies falling into this category, in my view, include BAE Systems (LSE:BA), GlaxoSmithKline, and Royal Dutch Shell.

As geopolitical tensions rise and technology advances, cyber-crime is an increasing threat. This makes me think defence is a good sector to invest in. BAE Systems regularly wins international government contracts, and I think this will continue. Concern surrounding government defence spending has been suppressing the BAE share price in recent months, but in the long term I think spending will increase. The UK is already looking at ways to divert budgets to defence and intelligence, and other governments may follow suit.

BAE’s technological advancements are not only impressive but vital in ensuring high-calibre solutions for aerospace, defence, and security markets. Interpol recently released a report warning that cybercriminal activity has increased amid Covid-19. Russia and China have been accused of hacking, and fake news is on the rise. All this points to a need for continued investment in national security. BAE recently reinstated its dividend which has a yield of 4.5%. Earnings per share are 46.4p and its price-to-earnings ratio (P/E) is 11.

Diversified sectors

GlaxoSmithKline is a science-led pharmaceutical giant creating medicines and vaccines, including a Covid-19 vaccine in partnership with Sanofi. It’s a £75bn company that continues to pay a dividend with a current yield of 5.4%. Earnings per share for the trailing 12 months sit at £1.32 and, based on this, GSK’s P/E is 11.

Now, we all know renewables are the future of energy, but oil remains indispensable in reaching that eventuality. Royal Dutch Shell has been around for decades and I believe it has the knowledge, experience, and budgets to continue to profit and adapt in this changing environment. I think it’s a sensible long-term buy and at 4.6%, it offers a decent dividend yield.

There are many companies that have thrived since the last stock market crash and I would begin my research by looking to those as potential buys in the next one.

Kirsteen owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »